Zealand Pharma A/S
ZEAL News Today: Stay Updated with the Latest Zealand Pharma A/S News in Real Time
Find ZEAL news now at Meyka AI. Stay informed with the latest Zealand Pharma A/S stocks updates, including price news, market analysis, and expert insights.
MediPal Holdings (MEPDF) Earnings Preview: EPS Seen at $0.24 on Pharma Demand
MediPal Holdings earnings preview: EPS estimate $0.24, revenue $5.62B expected May 14. Analyst expectations and what to watch.
NSRX Insider Trade: Rubin Eyal CFO Filing May 13, 2026
Nasus Pharma CFO Rubin Eyal files initial ownership of 40,549 share options valued at $306,550. Form 3 filing reveals executive equity stake.
Cipla Q4 Profit Slumps 55% YoY to ₹555 Crore Despite Dividend Announcement
Cipla Ltd reported its Q4 FY26 results for the quarter ending March 31, 2026. The company posted a sharp 55% year-on-year drop in net profit to about ₹555 crore. This decline has caught investor attention across the pharma sector. Despite weaker earnings, Cipla also announced a final dividend, adding a mixed signal for the market….
ROG.SW stock gains 0.5% on May 13 as Roche Holding AG trades actively
ROG.SW stock price at CHF322.3, up 0.5% today. Roche Holding AG trades 778,976 shares on SIX exchange with neutral B+ rating.
RIGL Maintained at Buy by H.C. Wainwright, May 2026
H.C. Wainwright maintains Buy rating on Rigel Pharmaceuticals (RIGL) following Pfizer Veppanu handoff announcement.
Goldline Pharmaceutical IPO Sees 22x Subscription on Day 1; GMP Signals Strong Listing Gains
The IPO of Goldline Pharmaceutical has become one of the most talked-about SME listings in the Indian primary market. On Day 1 of subscription, the issue reportedly saw a massive 22x oversubscription, showing strong demand from retail and high-net-worth investors. At the same time, the grey market premium (GMP) is signaling positive listing expectations, hinting…
ASARFI.BO Stock Plunges 21% on May 13, 2026 – BSE Top Loser
ASARFI.BO stock crashes 21% to ₹197.05 on BSE today. Asarfi Hospital Ltd. faces sharp selloff amid market volatility and weak technical signals.
OCS: H.C. Wainwright Maintains Buy Rating, May 2026
H.C. Wainwright maintains Buy rating on OCS, raising price target to $47 from $44. Oculis stock trades at $30.41.
PSG.DE Stock Holds €29 in Pre-Market, May 2026
PharmaSGP Holding SE (PSG.DE) trades at €29.0 on XETRA. Meyka AI rates it B+ with strong fundamentals and growth potential.